{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:08:37Z","timestamp":1791544117896,"version":"4.3.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>The cancer\/testis antigens (CTA) are a group of antigens expressed on germ cells of healthy testis and malignant tumors. We studied whether CTA are present on lentigo maligna (LM) and LM melanoma (LMM) samples. Immunohistochemical expression of a panel of CTA (MAGE-A1, A2- A3, NY-ESO-1, PRAME, SSX-2, and a MAGE-A antibody reactive with -A1, -A2, -A3, -A4, -A6, -A10, and -A12) was investigated in formalin-fixed paraffin-embedded samples from LMM (n = 20), LM (n = 8), chronically sun-exposed skin (n = 7), and healthy skin (n = 7). In 4 LMM lesions, the MAGE-A marker was positive. Another 3 LMM lesions were positive for MAGE-A1, MAGE-A2, and MAGE-A3. PRAME was positive in 18\/20 LMM and 6\/8 LM. We did not find expression of MAGE, NY-ESO-1, or SSX-2 in LM, thereby excluding these CTA as diagnostic markers to discern malignant melanocytes in LM from normal melanocytes. LMM did express MAGE, NY-ESO-1, and SSX-2. If a biopsy from a lesion suspect for LM shows positivity for MAGE, NY-ESO-1, and SSX-2, the lesion may actually be LMM. In contrast, PRAME expression was found in LM at low levels and in LMM at much higher levels, and absent in normal melanocytes. PRAME can potentially be used to discern normal melanocytes from malignant melanocytes.<\/jats:p>","DOI":"10.1097\/dad.0000000000001607","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T16:24:41Z","timestamp":1579191881000},"page":"625-627","source":"Crossref","is-referenced-by-count":33,"title":["Differential Expression of Cancer Testis Antigens on Lentigo Maligna and Lentigo Maligna Melanoma"],"prefix":"10.1097","volume":"42","author":[{"given":"Darryl","family":"Tio","sequence":"first","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Willemsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Krebbers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazira R.","family":"Kasiem","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hoekzema","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel W.","family":"Bekkenk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie M.","family":"Luiten","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2013Update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur J Cancer."},{"key":"R3-20230908","first-page":"39","article-title":"Lentigo maligna and lentigo-maligna melanoma","volume":"55","author":"Clark","year":"1969","journal-title":"Am J Pathol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jnci\/95.11.806","article-title":"Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma","volume":"95","author":"Whiteman","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jid.2013.338","article-title":"The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type","volume":"134","author":"Stadelmeyer","year":"2014","journal-title":"J Invest Dermatol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CMR.0000000000000569","article-title":"Expression of cancer\/testis antigens in cutaneous melanoma: a systematic review","volume":"29","author":"Tio","year":"2019","journal-title":"Melanoma Res."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjd.17714","article-title":"Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery","volume":"181","author":"Zoutendijk","year":"2019","journal-title":"Br J Dermatol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:17:46Z","timestamp":1694150266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001607","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,14]]}}}